Skip to main content

Advertisement

Table 1 Characteristics of subjects in the in vivo dataset

From: Impaired type I interferon regulation in the blood transcriptome of recurrent asthma exacerbations

  Single AETRI Non-infectious AEs Multiple AETRIs
  (N = 41) (N = 38) (N = 11)
Exacerbation samples (n) 41 38 27
Baseline samples (n) 147 124 32
Female Gender 28 (68%) 22 (58%) 9 (82%)
White Race 36 (88%) 33 (87%) 10 (91%)
BMI, kg/m2 27.7 [24.5–31.3] 27.8 [24.7–32.0] 34.2 [27.9–38.7]
GERD 8 (20%) 13 (34%) 6 (55%)
Atopy Status
 Atopic 27 (66%) 25 (66%) 8 (73%)
 Non-Atopic 9 (22%) 8 (21%) 1 (9%)
 Unknown 5 (12%) 5 (13%) 2 (18%)
Asthma Severity at the time of Exacerbation
 Mild Persistent 5 (12%) 2 (5%) 0 (0%)
 Moderate Persistent 20 (49%) 16 (42%) 4 (36%)
 Severe Persistent 16 (39%) 20 (53%) 7 (64%)
FEV1 predicted (%) 88 [65–98] 78 [62–87] 62 [45–95]
IgE level, IU/ml 107 [46–224] 117 [53–198] 64 [47–65]
Inhaled CS use 13 (32%) 19 (50%) 10 (91%)
Systemic CS use 15 (37%) 12 (32%) 4 (36%)
Leukotriene receptor antagonist use 15 (37%) 12 (32%) 4 (36%)
Maximum steroid exposure during an exacerbation
 Systemic 13 (32%) 19 (50%) 10 (91%)
 Inhaled 27 (66%) 19 (50%) 1 (9%)
 Other 1 (2%) 0 (0%) 0 (0%)
Bactin-GAPDH 5′ 3′ ratio exacerbation 0.86 [0.77–0.96] 0.84 [0.78–0.95] 0.86 [0.69–0.93]
Bactin-GAPDH 5′ 3′ ratio baseline 0.85 [0.70–0.93] 0.84 [0.73–0.92] 0.85 [0.73–0.92]
Ratio of M:L whole blood exacerbation 0.19 [0.15–0.32] 0.26 [0.15–0.31] 0.24 [0.20–0.33]
Ratio of M:L whole blood baseline 0.17 [0.13–0.22] 0.20 [0.15–0.26] 0.23 [0.21–0.26]
  1. Data are n (%) or median [25–75 interquartile range] unless otherwise specified
  2. Definition of Abbreviations: AETRI asthma exacerbation triggered by respiratory infection, AEs asthma exacerbations, BMI body mass index, GERD gastroesophageal reflux disease, FEV1 forced expiratory volume in 1 s, IgE immunoglobulin E, CS corticosteroids, GAPDH glyceraldehyde-3-phosphate dehydrogenase, M:L monocytes to lymphocytes